Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Trinity Biotech (TRIB) FCF Margin (2016 - 2024)

Trinity Biotech's FCF Margin history spans 16 years, with the latest figure at 23.59% for Q4 2024.

  • On a quarterly basis, FCF Margin rose 1942.0% to 23.59% in Q4 2024 year-over-year; TTM through Dec 2024 was 6.08%, a 1307.0% increase, with the full-year FY2025 number at 12.95%, down 549.0% from a year prior.
  • FCF Margin hit 23.59% in Q4 2024 for Trinity Biotech, up from 4.17% in the prior quarter.
  • Over the last five years, FCF Margin for TRIB hit a ceiling of 45.3% in Q4 2020 and a floor of 30.91% in Q3 2023.
  • Historically, FCF Margin has averaged 10.52% across 5 years, with a median of 6.35% in 2022.
  • Biggest five-year swings in FCF Margin: soared 3412bps in 2020 and later crashed -3725bps in 2023.
  • Tracing TRIB's FCF Margin over 5 years: stood at 45.3% in 2020, then tumbled by -45bps to 25.1% in 2021, then plummeted by -30bps to 17.56% in 2022, then plummeted by -76bps to 4.17% in 2023, then surged by 466bps to 23.59% in 2024.
  • Business Quant data shows FCF Margin for TRIB at 23.59% in Q4 2024, 4.17% in Q4 2023, and 30.91% in Q3 2023.